Bold, Guido published the artcileCGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777, and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis, Application In Synthesis of 300842-64-2, the publication is Drugs of the Future (2002), 27(1), 43-55, database is CAplus.
A review. The pharmacol. profile of the class of 1-anilino-(4-pyridylmethyl)-phthalazines is presented. 1-Anilino-(4-pyridylmethyl)phthalazines are potent, selective and orally well absorbed inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. In vitro they block VEGF-stimulated autophosphorylation of KDR expressing cells, resulting in the inhibition of survival effects of VEGF on endothelial cells. They also block platelet derived factor-mediated effects at slightly higher concentration but do not affect other pathways such as the bFGF receptor.
Drugs of the Future published new progress about 300842-64-2. 300842-64-2 belongs to phthalazine, auxiliary class Protein Tyrosine Kinase/RTK,VEGFR, name is N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, and the molecular formula is C21H17BrN4, Application In Synthesis of 300842-64-2.